Impact of very early high doses of recombinant erythropoietin on anemia and allograft function in de novo kidney-transplant patients

Transplant International

Volumn 23, Issue 3, 2010, Pages 277-284

  Kamar, Nassim ^a   Reboux, Anne Hélène ^a   Cointault, Olivier ^a   Esposito, Laure ^a   Cardeau Desangles, Isabelle ^a   Lavayssière, Laurence ^a   Guitard, Joëlle ^a   Wéclawiak, Hugo ^a   Rostaing, Lionel ^a,b  

^a CHU RANGUEIL   (France)

^b CHU PURPAN   (France)

Author keywords

Allograft function; Anemia; Erythropoietin stimulating agents; Kidney transplantation

Indexed keywords

BELATACEPT; CALCINEURIN INHIBITOR; COTRIMOXAZOLE; GANCICLOVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; RECOMBINANT ERYTHROPOIETIN; STEROID; THYMOCYTE ANTIBODY; VALACICLOVIR; VALGANCICLOVIR;

ADD ON THERAPY; ADULT; ALLOGRAFT; ANEMIA; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DRUG MEGADOSE; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; HYPERTENSION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; ORGAN DONOR; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; ANEMIA; CREATININE; ERYTHROPOIETIN, RECOMBINANT; FEMALE; GRAFT SURVIVAL; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 75149185907     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2009.00982.x     Document Type: Article

References (29)

1. Vanrenterghem Y, Ponticelli C, Morales JM, et al. Prevalence and management of anemia in renal transplant recipients: a European survey. Am J Transplant 2003 3: 835.
2. Turkowski-Duhem A, Kamar N, Cointault O, et al. Predictive factors of anemia within the first year post renal transplant. Transplantation 2005 80: 903.
3. Shah N, Al-Khoury S, Afzali B, et al. Posttransplantation anemia in adult renal allograft recipients: prevalence and predictors. Transplantation 2006 81: 1112.
4. Rigatto C. Anemia, renal transplantation, and the anemia paradox. Semin Nephrol 2006 26: 307.
5. Imoagene-Oyedeji AE, Rosas SE, Doyle AM, et al. Posttransplantation anemia at 12 months in kidney recipients treated with mycophenolate mofetil: risk factors and implications for mortality. J Am Soc Nephrol 2006 17: 3240.
6. Kamar N, Rostaing L. Negative impact of one-year anemia on long-term patient and graft survival in kidney-transplant patients receiving calcineurin inhibitors and mycophenolate mofetil. Transplantation 2008 85: 1120.
7. Chadban SJ, Baines L, Polkinghorne K, et al. Anemia after kidney transplantation is not completely explained by reduced kidney function. Am J Kidney Dis 2007 49: 301.
8. Ersoy A, Kahvecioglu S, Ersoy C, et al. Anemia due to losartan in hypertensive renal transplant recipients without posttransplant erythrocytosis. Transplant Proc 2005 37: 2148.
9. Khosroshahi HT, Asghari A, Estakhr R, et al. Effects of azathioprine and mycophenolate mofetil-immunosuppressive regimens on the erythropoietic system of renal transplant recipients. Transplant Proc 2005 38: 2077.
10. Augustine JJ, Rodriguez V, Padiyar A. Reduction in erythropoietin resistance after conversion from sirolimus to enteric coated mycophenolate sodium. Transplantation 2008 86: 548.
11. Clinical practice recommendations for anemia in chronic kidney disease in transplant recipients. KDOQI; National Kidney Foundation. Am J Kidney Dis 2006 47 (5 Suppl 3 S109.
12. McDevitt LM, Smith LD, Somerville KT, Corbett JL, Shihab FS. A retrospective assessment of pre-treatment variables on the response to darbepoetin alfa after renal transplantation. Am J Transplant 2005 5: 1948.
13. Schwenger V, Morath C, Zeier M. Use of erythropoietin after solid organ transplantation. Nephrol Dial Transplant 2007 22 (Suppl. 8 viii47.
14. Baltar J, Moran N, Ortega T, et al. Erythropoietin safety and efficacy in chronic allograft nephropathy. Transplant Proc 2007 39: 2245.
15. Ribes D, Kamar N, Guitard J, Esposito L, Rostaing L. Darbepoetin-alfa in renal-transplant patients: an observational monocentric study. Clin Nephrol 2008 69: 102.
16. Kamar N, Guitard J, Ribes D, Esposito L, Rostaing L. A monocentric observational study of darbepoetin alfa in anemic hepatitis-C-virus transplant patients treated with ribavirin. Exp Clin Transplant 2008 6: 271.
17. Van Biesen W, Vanholder R, Veys N, Verbeke F, Lameire N. Efficacy of erythropoietin administration in the treatment of anemia immediately after renal transplantation. Transplantation 2005 79: 367.
18. Van Loo A, Vanholder R, Bernaert P, De Roose J, Lameire N. Recombinant human erythropoietin corrects anaemia during the first weeks after renal transplantation: a randomized prospective study. Nephrol Dial Transplant 1996 11: 1815.
19. Afzali B, al-Khoury S, Shah N, et al. Anemia after renal transplantation. Am J Kidney Dis 2006 48: 519.
20. Sun CH, Ward HJ, Paul WL, et al. Serum erythropoietin levels after renal transplantation. N Engl J Med 1989 321: 151.
21. Besarab A, Caro J, Jarell BE, Francos G, Erslev AJ. Dynamics of erythropoiesis following renal transplantation. Kidney Int 1987 32: 526.
22. Al-Uzri A, Yorgin PD, Kling PJ. Anemia in children after transplantation: etiology and the effect of immunosuppressive therapy on erythropoiesis. Pediatr Transplant 2003 7: 253.
23. Ruggenenti P, Codreanu I, Cravedi P, et al. Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation. Clin J Am Soc Nephrol 2006 1: 546.
24. Winkelmayer WC, Kewalramani R, Rutstein M, et al. Pharmacoepidemiology of anemia in kidney transplant recipients. J Am Soc Nephrol 2004 15: 137.
25. A-Khoury S, Shah N, Afzali lB, Covic A, Taylor J, Goldsmith D. Post-transplantation anaemia in adult and paediatric renal allograft recipients: Guy's Hospital experience. Nephrol Dial Transplant 2006 21: 1974.
26. Sharples EJ, Yaqoob MM. Erythropoietin in experimental acute renal failure. Nephron Exp Nephrol 2006 104: e83.
27. Salahudeen AK, Haider N, Jenkins J, et al. Antiapoptotic properties of erythropoiesis-stimulating proteins in models of cisplatin-induced acute kidney injury. Am J Physiol Renal Physiol 2008 294: F1354.
28. Kiris I, Kapan S, Kilbas A, et al. The protective effect of erythropoietin on renal injury induced by abdominal aortic-ischemia-reperfusion in rats. J Surg Res 2008 149: 206.
29. Johnson DW, Pat B, Vesey DA, et al. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 2006 69: 1806.